Who is sponsoring NCT05499065?

NCT05499065 is sponsored by University Medical Center Groningen.

What condition does NCT05499065 study?

NCT05499065 studies Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.

Is NCT05499065 still recruiting?

NCT05499065 is currently completed. Last updated 31 May 2025.

Last reviewed 2025-05-31 · How we verify

NCT05499065: LIGHTNING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-time Margin Assessment in Head and Neck Cancer

Completed Phase 2 Last updated 31 May 2025

What this trial tests

Phase 2 trial testing Fluorescence guided detection of tumor positive margins in Head and Neck Cancer in 23 participants. Completed in 10 January 2025.

Timeline

1 March 2023

Primary endpoint
23 October 2024

10 January 2025

Quick facts

Lead sponsor	University Medical Center Groningen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	1 March 2023
Primary completion	23 October 2024
Estimated completion	10 January 2025
Sites	1 location across Netherlands

Drugs / interventions tested

Fluorescence guided detection of tumor positive margins
Cetuximab-IRDye800 — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →

Sponsor

University Medical Center Groningen

Who can join

18 and older, any sex, with Head and Neck Cancer or Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate if the combination of fresh frozen sectioning based on cetuximab-800CW can enhance tumor-positive margin detection intra-operatively.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
Giuliani S, Paraboschi I, McNair A, Smith M, et al · · 2024 · cited 14× · PMID 38473402 · DOI 10.3390/cancers16051045
Systematic comparison of fluorescence imaging in the near-infrared and shortwave-infrared spectral range using clinical tumor samples containing cetuximab-IRDye800CW.
Keizers B, Nijboer TS, van der Fels CAM, van den Heuvel MC, et al · · 2025 · cited 7× · PMID 39553388 · DOI 10.1117/1.jbo.30.s1.s13708
Increasing the Dye Payload of Cetuximab-IRDye800CW Enables Photodynamic Therapy.
Nguyen A, Bhandari C, Keown M, Malkoochi A, et al · · 2024 · cited 6× · PMID 38861020 · DOI 10.1021/acs.molpharmaceut.4c00046
Intraoperative fluorescence-guided fresh frozen sectioning for margin control in head and neck cancer: phase 2 clinical trial.
Nijboer TS, Keizers B, Boeve K, Roos D, et al · · 2026 · PMID 41807438 · DOI 10.1038/s41467-026-70264-y
Compatibility of fast tissue clearing with targeted fluorescence imaging and pathology analysis using clinical head and neck cancer biopsies.
Fakhrolmobasheri A, Nijboer TS, Keizers B, Kooij RM, et al · · 2025 · PMID 41276579 · DOI 10.1038/s41598-025-27809-w

Verify or expand the search:

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other University Medical Center Groningen trials

Trials by the same sponsor.

NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05499065 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
Last refreshed: 31 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05499065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing